Atea Pharmaceuticals, Inc. (AVIR)
After hours:
| Previous Close | 4.5500 |
| Open | 4.5700 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1100 |
| Day's Range | 4.3600 - 4.5700 |
| 52 Week Range | 4.1750 - 9.7900 |
| Volume | |
| Avg. Volume | 448,035 |
| Market Cap | 377.293M |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 13.32 |
| EPS (TTM) | 0.3400 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.33 |
- GlobeNewswire
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:00 p.m. ET. A live webcast of the presentation will be avai
- GlobeNewswire
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination Trial of Bemnifosbuvir and Ruzasvir in Patients Infected with Hepatitis C Virus (HCV) with Initial Results Anticipated 4Q23 BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq:
- GlobeNewswire
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company’s website at www.atea
